

October 26, 2017



CohBar, Inc. to Announce Third Quarter 2017 Financial Results and Host Conference Call for Shareholders on November 13, 2017

MENLO PARK, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- CohBar, Inc. (OTCQX:CWBR) (TSXV:COB.U), an innovative biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the Company will release its third quarter 2017 financial results on Monday, November 13, 2017 and will host a conference call for the shareholders at 2:00 p.m. (Pacific Time) the same day to provide an update on its lead program, emerging pipeline and business.

Details for the Conference Call and Slide Presentation:

Date: November 13, 2017

Time: 2:00 p.m. (Pacific Time)

Audio, Dial-in U.S. and Canada: 1-888-599-8667

Audio, Dial-in International: 1-719-325-2494

Conference ID# 6432383

Slide Presentation – go to www.webex.com, click on the ‘Join’ button and enter **Meeting Number** 921656999 and **Password** Q3Call.

For individuals participating in the Investor Call and Slide Presentation, we request you please call into the audio and log into WebEx approximately 10 minutes before the start of the presentation so that we can begin promptly.

An audio replay of the call will be available beginning at 6:00 p.m. (Pacific Time) on November 13, 2017, through 9:00 p.m. (Pacific Time) on November 27, 2017. To access the recording please dial 1-844-512-2921 in the U.S. and Canada or 1-412-317-6671 internationally and reference Conference ID# 6432383.

The audio replay along with the slide presentation will also be available at www.cohbar.com beginning November 14, 2017 through November 27, 2017.

About CohBar

CohBar (OTCQX:CWBR) (TSXV:COB.U) is an innovative biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age.

CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease (NASH), type 2 diabetes, cancer, cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than 100 biologically active MDPs.

For additional company information, please visit www.cohbar.com.

Investor and Media Contact:

Jeff Biunno, CFO

CohBar, Inc.

(650) 446-7888 ext. 109

jeff.biunno@cohbar.com



Source: CohBar, Inc.